Compare NWSA & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NWSA | IONS |
|---|---|---|
| Founded | 2012 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Newspapers/Magazines | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.9B | 12.9B |
| IPO Year | N/A | 1991 |
| Metric | NWSA | IONS |
|---|---|---|
| Price | $26.11 | $79.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 22 |
| Target Price | $37.34 | ★ $82.82 |
| AVG Volume (30 Days) | ★ 3.7M | 1.8M |
| Earning Date | 02-04-2026 | 02-18-2026 |
| Dividend Yield | ★ 0.76% | N/A |
| EPS Growth | ★ 230.83 | N/A |
| EPS | ★ 2.06 | N/A |
| Revenue | ★ $8,500,000,000.00 | $966,957,000.00 |
| Revenue This Year | $5.13 | $29.72 |
| Revenue Next Year | $3.30 | $0.97 |
| P/E Ratio | $12.82 | ★ N/A |
| Revenue Growth | 2.20 | ★ 20.41 |
| 52 Week Low | $23.38 | $23.95 |
| 52 Week High | $31.61 | $83.61 |
| Indicator | NWSA | IONS |
|---|---|---|
| Relative Strength Index (RSI) | 49.74 | 52.74 |
| Support Level | $26.13 | $78.52 |
| Resistance Level | $26.50 | $82.09 |
| Average True Range (ATR) | 0.38 | 1.82 |
| MACD | 0.04 | -0.32 |
| Stochastic Oscillator | 45.06 | 50.60 |
News Corporation is a diversified media conglomerate with large presence in the US, the UK, and Australia. Key mastheads include The Wall Street Journal, Barron's, New York Post, The Times, The Sun, The Australian, Herald Sun, and The Daily Telegraph. Its 61%-owned REA Group is the dominant property listings business in Australia. In addition, it owns Harper Collins, one of the largest book publishers in the world, and has a sizable US digital property advertising business, Move. The 65% interest in Foxtel, the Australian pay-TV and streaming provider, was sold in April 2025. The sale to global sports streaming platform, DAZN, was struck at more than 7 times Foxtel's EBITDA.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.